Home > Healthcare & Medical Devices > Pregnancy Medication Market

Pregnancy Medication Market Size By Drug Class (Antianemia, Antacids, Antiallergic, Analgesics, Antimicrobials, Hormones, Laxatives, Vaccines, Nutritional Supplements {Minerals, Omega 3, Folic Acid, Vitamins, Multivitamins}), By Pregnancy Stage (1st Trimester, 2nd Trimester, 3rd Trimester), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI5385
  • Published Date: Oct 2022
  • Report Format: PDF

Industry Overview

Pregnancy Medication Market size was valued at over USD 33 billion in 2022 and is poised to witness 13% CAGR from 2023 to 2032.
 

Rapid development in incidences of pregnancy-associated complications is expected to drive the demand for pregnancy medication. Based on estimates by the World Health Organization, every day, almost 800 women worldwide die due to complications during childbirth. These intricacies are 36 times more prevalent in developing economies than in developed countries. The alarming progress in childbirth-related complications can be attributed to improper dietary habits, physical inactivity, and the rising adoption of a sedentary lifestyle.
 

Pregnancy Medication Market

Get more details on this report - Request Free Sample PDF
 

Consumption of unhealthy food during pregnancy can increase the risk of developing various long-term irreversible health issues. These may range from high blood pressure, cholesterol, heart diseases, and type 2 diabetes to defective childbirth. The rapid inclination toward maintaining a proper nutritional diet rich in all micro and macronutrients to support the health of the mother and the fetus will create positive growth prospects for the pregnancy medication industry.
 

Consumption of other OTC drugs may act as a restraining factor

The intake of other medications and the possible side effects and health risks associated with them may limit the pregnancy medication market value. A significant share of pregnant women consumes over-the-counter drugs for several comorbidities, such as CVDs, which are one of the leading causes of death among pregnant women. These medications may also lead to premature birth, low birth weight, stillbirth, and other complications, which may downsize the market share.
 

Rising focus on minimizing childbirth complexities to increase the sales of nutritional supplements

Pregnancy Medication Market by Nutritional Supplements

Get more details on this report - Request Free Sample PDF
 

Pregnancy medication market from nutritional supplements segment garnered revenues worth over USD 16.5 billion in 2022. Nutritional supplements comprising omega-3, vitamins, minerals, folic acid, multivitamins, and others support the development of the placenta and fetus while preventing the risk of neural tube defects. The growing emphasis on maintaining a healthy diet to minimize the prospects of birth defects and improper nutrition in babies will propel the segment size.
 

Severe health complications to boost the intake of pregnancy medications during 2nd-trimester

Pregnancy Medication Market by Pregnancy Stage

Get more details on this report - Request Free Sample PDF
 

The 2nd-trimester segment is expected to exhibit over 13% CAGR from 2023 to 2032. The intake of pregnancy medications and supplements in the 2nd-trimester improves sensory gating and reduces the risk of later attention deficits and psychological disorders. Health complications such as separation of the placenta from the uterus, increased preterm labor, and other risk factors are quite prevalent during the 4th to 6th months of pregnancy. Hence, in light of these complications, the pregnancy medication demand will accelerate throughout the projection period.
 

Cost-effective prescription and treatment may bolster the popularity of retail pharmacies

Pregnancy Medication Market by Distribution Channel

Get more details on this report - Request Free Sample PDF
 

Pregnancy medication market from retail pharmacy segment is anticipated to amass nearly 28% business share by 2032. Retail pharmacies are easily accessible to patients and have the availability of a broad range of healthcare products and everyday items. These establishments are equipped with skilled pharmacists offering uniquely tailored personalized advice to patients based on their health issues. Access to high-quality consumer service at affordable prices across these settings will help retail pharmacies emerge as major expansion contributors in the ensuing years.
 

Improving dietary regimes to spur industry statistics across Europe

Pregnancy Medication Market by Region

Get more details on this report - Request Free Sample PDF
 

Europe pregnancy medication market is slated to cross USD 23 billion by 2032. The increasing number of market participants organizing social media campaigns and health initiatives to create awareness about proper health and diet among pregnant women will stimulate the regional market landscape. In addition, the growing incidences of birth defects and congenital anomalies, coupled with the availability of high-quality health supplements, will positively influence the industry dynamics across Europe.
 

Acquisitions to strengthen the competitive landscape

Major companies participating in the pregnancy medication industry are Alkem Laboratories Limited, Piramal Enterprises Limited, F.Hoffman-La Roche Ltd, Pfizer, Dr. Reddy’s Laboratories, Cipla Inc, Alembic Pharmaceuticals Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Viatris Inc., (Mylan Inc.),  and Amgen Inc.These players have been adopting brand acquisitions, mergers, and collaboration as part of their key growth strategy.
 

For instance, in June 2022, Glenmark Pharmaceuticals Ltd. and its U.S. subsidiary announced the acquisition of Wockhardt Ltd.'s generic interpretations of 4 OTC drugs. The move designated the continued expansion of the firm's over-the-counter business in the U.S., comprising vitamins, minerals, and other products.
 

COVID-19 impact assessment on the pregnancy medication market trends

The COVID-19 pandemic had a favorable impact on the pregnancy medication industry. This can be credited to the rapid surge in pregnancies during the crisis and the rising awareness about the benefits of nutritional supplements in child growth and development. Based on a poll conducted by United Nations, several countries such as China, Pakistan, and India have witnessed a visible rise in the number of pregnancies during lockdowns, with nearly 13.5 million, 5 million, and 7 million pregnancies registered during the given period. The increasing sales of prenatal supplements to eliminate prospective childbirth complications may further boost the market outlook.
 

The pregnancy medication market report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments:

By Drug Class

  • Antianemia
  • Antacids
  • Antiallergic
  • Analgesics
  • Antimicrobials
  • Hormones
  • Laxatives
  • Vaccines
  • Nutritional Supplements
    • Minerals
    • Omega 3
    • Folic Acid
    • Vitamins
    • Multivitamins
    • Others
  • Others

By Pregnancy Stage

  • 1st trimester
  • 2nd trimester
  • 3rd trimester

By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Others
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market size for pregnancy medication exceeded USD 33 billion in 2022 and is projected to exhibit around 13% CAGR from 2023 to 2032 owing to the surging incidences of complexities associated with pregnancy and childbirth.

Nutritional supplements segment was worth over USD 16.5 billion in 2022 and is anticipated to amass significant market share by 2032 due to the proven benefits of nutritional supplements in supporting healthy fetal growth and preventing the prospects of neural tube defects.

Retail pharmacy segment is predicted to hold around 28% market share by 2032, driven by the availability of a wide range of health products and customized prescription and treatment at affordable prices.

Notable players in the pregnancy medication MARKET are Alkem Laboratories Limited, Piramal Enterprises Limited, F.Hoffman-La Roche Ltd, Pfizer, Dr. Reddy’s Laboratories, Cipla Inc, Alembic Pharmaceuticals Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Viatris Inc., (Mylan Inc.), Amgen Inc., and others.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies
Immediate Delivery Available

Premium Report Details

  • Base Year: 2022
  • Companies covered: 12
  • Tables & Figures: 261
  • Countries covered: 18
  • Pages: 255

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount